Sinovac Evaluating Competing Take-Private Offers
This article was originally published in PharmAsia News
Executive Summary
Beijing-based vaccines group Sinovac Biotech is evaluating two privatization proposals after competing offers from its CEO and an EV17 vaccine rival have emerged in recent days.